Video

Dr. Grothey Discusses Novel Agents for Colorectal Cancer

Dr. Axel Grothey from the Mayo Clinic Discusses Novel Agents for Colorectal Cancer

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the novel agents being investigated for colorectal cancer (CRC). There has not been a new agent for CRC since the approval of cetuximab and bevacizumab 7 1/2 years ago.

Recently there have been numerous advances in what was previously a very stagnant field. One of the most important discoveries is that KRAS mutated tumors do not respond to epidermal growth factor receptor (EGFR) inhibitor drugs such as cetuximab and panitumumab.

Aflibercept, a novel agent currently under investigation, binds to the VEGF-A ligand, VEGF-B, and the placental growth factor (PIGF). Adding aflibercept to FOLFIRI in metastatic CRC patients resulted in significantly improved outcomes in the second-line setting.

The oral multikinase inhibitor named regorafenib demonstrated overall survival in heavily pretreated metastatic CRC; these patients currently do not have any clinical options. The data from the phase III trial, which was stopped early because of positive data, will be released at ASCO GI 2012.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity